

AI-powered disease and care simulation for faster and value-based clinical development and market access

#### **SIMULATE**

Future Compounds in RW

#### **PREDICT**

Public Health & Economic Impact Al-powered disease and care models

## **EMULATE**

Clinical Trials using RWD

#### **PROJECT**

Long-Term Benefit / Risk

### Clinical Development

**Optimization Solutions** 

- Enrich trial populations for higher generalizability, external validity, faster recruitment and better regulatory acceptance
- Optimize endpoints i.e., more sensitive vs drug value (e.g., surrogate endpoint definition)
- Project long-term outcomes for de-risked and value-based trials
- Synthetic control arms e.g. for rare diseases

#### Benefit/Risk

**Projection Solutions** 

- Label defense and extension via patients profiling vs long-term benefit/risk projections
- Project public health impact and demonstrate long-term medical value
- Optimize switching times via what if scenarios simulations and treatment sequences comparison

#### **Asset Lifecycle Value**

Management Solutions

- Optimize Target Product Profile by testing TPP differentiation scenarios via simulation
- Characterize and project high value patients in real-world

## **Our references**

























# Quinten Health: a trusted data science partner

- Fast results that answer research & business questions to assist decision-making
- Experience across all therapeutic areas
- Knowledge extraction from 30+ Real World Databases & 100+ RCTs
- 400+ projects for 60 organisations across healthcare system
- Proprietary algorithms and frameworks
- An optimal combination of mastered analytical approaches
- Priority given to **interpretable** models







8 rue Vernier 75017 Paris, France +33 1 45 74 33 05 www.quinten-health.com





Alexandre Templier President a.templier@quinten-france.com b.amzal@quinten-health.com



Billy Amzal CEO



Frank Ahrens **Chief Commercial Officer** f.ahrens@quinten-health.com